Trials / Completed
CompletedNCT00150267
A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 976 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To estimate the frequency of patients with ocular/periorbital adverse events. To identify any possible long-term adverse consequences of increased iris pigmentation and to follow serious adverse events throughout the study period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xalacom |
Timeline
- Start date
- 2002-02-01
- First posted
- 2005-09-08
- Last updated
- 2008-11-05
Locations
74 sites across 12 countries: Australia, Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Netherlands, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00150267. Inclusion in this directory is not an endorsement.